Skip to content
value.today

Muse Biotechnology, Inc.

🇺🇸 Denver, Colorado, USABiotechnologyFounded 2015
Total raised
$438 M
10 rounds on record
Latest round
$2 M
Nov 2021
First round on record
Apr 2016
Today
Private
No later event on record

Funding rounds

10 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Muse Biotechnology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$28 MIssued in a merger or acquisition$10 to $50 million

Muse Biotechnology, Inc.: Private sale, Dec 2022

Investors in this round

5 investors had bought by the notice of Jan 18, 2023: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Justin Ferber · Executive Officer
  • Ron McGrath · Executive Officer
  • Sri Kosaraju · Executive Officer, Director
  • Bryan L. Roberts · Director
  • John R. Stuelpnagel · Director
  • Kristala L. Jones Prather · Director
  • Roger R. Wyse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 18, 2023. Read the notice at the SEC.

equity, optionsSEC
Dec 2022$4 MIssued in a merger or acquisition$2 to $10 million

Muse Biotechnology, Inc.: Private sale, Dec 2022

Investors in this round

4 investors had bought by the notice of Jan 18, 2023: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Justin Ferber · Executive Officer
  • Ron McGrath · Executive Officer
  • Sri Kosaraju · Executive Officer, Director
  • Bryan L. Roberts · Director
  • John R. Stuelpnagel · Director
  • Kristala L. Jones Prather · Director
  • Roger R. Wyse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 18, 2023. Read the notice at the SEC.

equitySEC
Nov 2021$2 MNo. 10Under $2 million

Muse Biotechnology, Inc.: Raise no. 10, Nov 2021

Investors in this round

2 investors had bought by the notice of Jun 1, 2023: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Justin Ferber · Executive Officer
  • Sri Kosaraju · Executive Officer, Director
  • Bryan L. Roberts · Director
  • John R. Stuelpnagel · Director
  • Kristala L. Jones Prather · Director
  • Roger R. Wyse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer.”

Signed by Justin Ferber, General Counsel. Source: SEC Form D, newest notice filed Jun 1, 2023. Read the notice at the SEC.

optionsSEC
Mar 2021$150 MNo. 9$50 to $250 million

Muse Biotechnology, Inc.: Raise no. 9, Mar 2021

Investors in this round

32 investors had bought by the notice of Apr 14, 2021: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$150 M of $150 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dianna L. DeVore · Executive Officer
  • Michael R. Graige · Executive Officer
  • Ron R. McGrath · Executive Officer
  • Sri Kosaraju · Executive Officer, Director
  • Bryan L. Roberts · Director
  • John R. Stuelpnagel · Director
  • Roger R. Wyse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 14, 2021. Read the notice at the SEC.

equitySEC
Nov 2020$50 MNo. 8$50 to $250 million

Muse Biotechnology, Inc.: Raise no. 8, Nov 2020

Investors in this round

6 investors had bought by the notice of Nov 30, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dianna L. DeVore · Executive Officer
  • Michael R. Graige · Executive Officer
  • Ron R. McGrath · Executive Officer
  • Sri Kosaraju · Executive Officer, Director
  • Bryan L. Roberts · Director
  • John R. Stuelpnagel · Director
  • Roger R. Wyse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 30, 2020. Read the notice at the SEC.

equitySEC
Oct 2020$8 MNo. 7$2 to $10 million

Muse Biotechnology, Inc.: Raise no. 7, Oct 2020

Investors in this round

1 investor had bought by the notice of Nov 30, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dianna L. DeVore · Executive Officer
  • Michael R. Graige · Executive Officer
  • Ron R. McGrath · Executive Officer
  • Sri Kosaraju · Executive Officer, Director
  • Bryan L. Roberts · Director
  • John R. Stuelpnagel · Director
  • Roger R. Wyse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer.”

Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 30, 2020. Read the notice at the SEC.

optionsSEC
Nov 2019$92 MNo. 6$50 to $250 million

Muse Biotechnology, Inc.: Raise no. 6, Nov 2019

Investors in this round

12 investors had bought by the notice of Dec 11, 2019: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$92 M of $125 M offered; $33 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dianna D. DeVore · Executive Officer
  • Jason T. Gammack · Executive Officer
  • Kevin D. Ness · Executive Officer, Director
  • Michael T. Graige · Executive Officer
  • Ron T. McGrath · Executive Officer
  • Bryan D. Roberts · Director
  • John R. Stuelpnagel · Director
  • Roger R. Wyse · Director
  • Andrew D. Garst · Promoter
  • Ryan T. Gill · Promoter
  • Tanya T. Lipscomb · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 11, 2019. Read the notice at the SEC.

equitySEC
Jan 2019$50 MNo. 5$50 to $250 million

Muse Biotechnology, Inc.: Raise no. 5, Jan 2019

Investors in this round

14 investors had bought by the notice of Apr 15, 2019: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dianna D. DeVore · Executive Officer
  • Jason T. Gammack · Executive Officer
  • Kevin D. Ness · Executive Officer, Director
  • Michael T. Graige · Executive Officer
  • Bryan D. Roberts · Director
  • John R. Stuelpnagel · Director
  • Roger R. Wyse · Director
  • Andrew D. Garst · Promoter
  • Ryan T. Gill · Promoter
  • Tanya T. Lipscomb · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Apr 15, 2019. Read the notice at the SEC.

equitySEC
Aug 2018$1 MIssued in a merger or acquisitionUnder $2 million

Muse Biotechnology, Inc.: Private sale, Aug 2018

Investors in this round

9 investors had bought by the notice of Sep 17, 2018: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dianna D. DeVore · Executive Officer
  • Kevin D. Ness · Executive Officer, Director
  • Bryan D. Roberts · Director
  • John R. Stuelpnagel · Director
  • Roger R. Wyse · Director
  • Andrew D. Garst · Promoter
  • Ryan T. Gill · Promoter
  • Tanya T. Lipscomb · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 17, 2018. Read the notice at the SEC.

equitySEC
Feb 2018$56 MNo. 4$50 to $250 million

Muse Biotechnology, Inc.: Raise no. 4, Feb 2018

Investors in this round

14 investors had bought by the notice of Mar 7, 2018: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$56 M of $56 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dianna R. DeVore · Executive Officer
  • Kevin D. Ness · Executive Officer, Director
  • Ryan T. Gill · Executive Officer, Director, Promoter
  • Tanya T. Lipscomb · Executive Officer, Promoter
  • Bryan D. Roberts · Director
  • John R. Stuelpnagel · Director
  • Roger T. Wyse · Director
  • Andrew D. Garst · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 7, 2018. Read the notice at the SEC.

equitySEC
Feb 2017$23 MNo. 3$10 to $50 million

Muse Biotechnology, Inc.: Raise no. 3, Feb 2017

Investors in this round

10 investors had bought by the notice of Mar 1, 2017: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin D. Ness · Executive Officer, Director
  • Ryan T. Gill · Executive Officer, Director, Promoter
  • Bryan D. Roberts · Director
  • Eric T. Moessinger · Director
  • John D. Stuelpnagel · Director
  • Roger T. Wyse · Director
  • Andrew D. Garst · Promoter
  • Tanya T. Lipscomb · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 1, 2017. Read the notice at the SEC.

equitySEC
Nov 2016$1 MNo. 2Under $2 million

Muse Biotechnology, Inc.: Raise no. 2, Nov 2016

Investors in this round

1 investor had bought by the notice of Mar 7, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dianna R. DeVore · Executive Officer
  • Kevin D. Ness · Executive Officer, Director
  • Ryan T. Gill · Executive Officer, Director, Promoter
  • Tanya T. Lipscomb · Executive Officer, Promoter
  • Bryan D. Roberts · Director
  • John R. Stuelpnagel · Director
  • Roger T. Wyse · Director
  • Andrew D. Garst · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer.”

Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 7, 2018. Read the notice at the SEC.

optionsSEC
Apr 2016$6 MNo. 1$2 to $10 million

Muse Biotechnology, Inc.: Raise no. 1, Apr 2016

Investors in this round

2 investors had bought by the notice of May 11, 2016: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ryan T. Gill · Executive Officer, Director, Promoter
  • Tanya T. Lipscomb · Executive Officer, Director, Promoter
  • Eric T. Moessinger · Director
  • Roger T. Wyse · Director
  • Andrew D. Garst · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ryan T. Gill, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 11, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Muse Biotechnology, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2023).

    SEC Form D · Jun 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2023

That is all the official record says: Muse Biotechnology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Muse Biotechnology, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 10 rounds above had up to 32 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Muse Biotechnology, Inc.
NameRoleNamed in
Justin FerberExecutive officerJun 2023
Sri KosarajuExecutive officerJun 2023
Ron McGrathExecutive officerJan 2023
Dianna L. DeVoreExecutive officerApr 2021
Michael R. GraigeExecutive officerApr 2021
Ron R. McGrathExecutive officerApr 2021
Dianna D. DeVoreExecutive officerDec 2019
Jason T. GammackExecutive officerDec 2019
Kevin D. NessExecutive officerDec 2019
Michael T. GraigeExecutive officerDec 2019
Ron T. McGrathExecutive officerDec 2019
Dianna R. DeVoreExecutive officerMar 2018
Ryan T. GillExecutive officerMar 2018
Tanya T. LipscombExecutive officerMar 2018
Bryan L. RobertsDirectorJun 2023
John R. StuelpnagelDirectorJun 2023
Kristala L. Jones PratherDirectorJun 2023
Roger R. WyseDirectorJun 2023
Sri KosarajuDirectorJun 2023
Bryan D. RobertsDirectorDec 2019
Kevin D. NessDirectorDec 2019
Roger T. WyseDirectorMar 2018
Ryan T. GillDirectorMar 2018
Eric T. MoessingerDirectorMar 2017
John D. StuelpnagelDirectorMar 2017
Tanya T. LipscombDirectorMay 2016
Andrew D. GarstPromoterDec 2019
Ryan T. GillPromoterDec 2019
Tanya T. LipscombPromoterDec 2019